Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
Pierre Laurent-PuigMarie-Lise GrisoniVolker HeinemannFrançois LiebaertDaniel NeureiterAndreas JungFrançois MontestrucYann Gaston-MatheRaphaële ThiébautSebastian StinzingPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
MiR-31-3p expression level was validated as a predictive biomarker of cetuximab therapy efficacy for patients with RAS WT mCRC.